Previous Article | Next Article 
Molecular and Cellular Biology, October 2000, p. 7132-7139, Vol. 20, No. 19
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Coiled-Coil Domain of Stat3 Is Essential for
Its SH2 Domain-Mediated Receptor Binding and Subsequent Activation
Induced by Epidermal Growth Factor and Interleukin-6
Tong
Zhang,
Wei Hua
Kee,
Kah Tong
Seow,
Winnie
Fung,
and
Xinmin
Cao*
Institute of Molecular and Cell Biology,
Singapore 117609, Singapore
Received 7 March 2000/Returned for modification 19 April
2000/Accepted 20 June 2000
 |
ABSTRACT |
STAT proteins are a family of latent transcription factors that
mediate the response to various cytokines and growth factors. Upon
stimulation by cytokines, STAT proteins are recruited to the receptors
via their SH2 domains, phosphorylated on a specific tyrosine,
dimerized, and translocated into the nucleus, where they bind specific
DNA sequences and activate the target gene transcription. STATs share
highly conserved structures, including an N-domain, a coiled-coil
domain, a DNA-binding domain, a linker domain, and an SH2 domain. To
investigate the role of the coiled-coil domain, we performed a
systematic deletion analysis of the N-domain and each of the
-helices and mutagenesis of conserved residues in the coiled-coil
region of Stat3. Our results indicate that the coiled-coil domain is
essential for Stat3 recruitment to the receptor and the subsequent
tyrosine phosphorylation and tyrosine phosphorylation-dependent
activities, such as dimer formation, nuclear translocation, and DNA
binding, stimulated by epidermal growth factor (EGF) or interleukin-6
(IL-6). Single mutation of Asp170 or, to a lesser extent, Lys177 in
-helix 1 diminishes both receptor binding and tyrosine
phosphorylation. Furthermore, the Asp170 mutant retains its ability to
bind to DNA when phosphorylated on Tyr705 by Src kinase in vitro,
implying a functional SH2 domain. Finally, we demonstrate a direct
binding of Stat3 to the receptor. Taken together, our data reveal a
novel role for the coiled-coil domain that regulates the early events
in Stat3 activation and function.
 |
INTRODUCTION |
Growth factors and cytokines
regulate cell growth and differentiation by triggering various
intracellular signaling pathways that lead to gene expression. JAK-STAT
is a key pathway that mediates cellular responses to a variety of
cytokines (reviewed in references 11, 20, and
30). As the name suggests, STATs (signal transducers and activators of transcription) represent a family of proteins with
dual functions that transduce the signal in the cytoplasm and activate
gene expression in the nucleus. Seven STATs with different functions
have been identified so far in mammalian cells, and over 40 different
polypeptides are known to activate one or more STATs (reviewed in
reference 10). Among them, Stat3 was identified both
as an acute-phase response factor activated by interleukin-6 (IL-6) in
mouse liver and by homology to Stat1 (2, 46). Stat3 is also
activated by other members of the IL-6 family, such as IL-11, ciliary
neurotrophic factor, oncostatin M, and leukemia-inhibitory factor,
which share the common transducing gp130 receptor subunit (2, 25,
33). IL-6, as a pleiotropic cytokine, exhibits various functions
in immune response, hematopoiesis, and neuronal differentiation
(37).
The model of activation of Stat3 by IL-6 has been established. Binding
of IL-6 to its receptor gp80 (subunit
) induces homodimerization of
gp130 (subunit
) and phosphorylation of the gp130-associated Janus
kinases (JAKs). JAKs phosphorylate the tyrosine residues on gp130 that
serve as docking sites for Stat3. Stat3 binds to the respective
tyrosine residues on gp130 through its Src homology 2 (SH2) domain and
is subsequently phosphorylated on a single tyrosine residue at the
carboxyl terminus by the JAKs (25, 33, 34). Stat3 forms
homo- or heterodimers with Stat1 via reciprocal interactions between
the SH2 domain and the phosphorylated tyrosine (31) and
translocates into the nucleus, where it binds to IL-6 response elements
and regulates many acute-phase protein genes (2). Growth
factors such as epidermal growth factor (EGF), platelet-derived growth
factor, and colony-stimulating factor (CSF-1) can also activate Stat3
(29, 46). It has been reported that Stat1 interacts with the
EGF receptor, and the intrinsic tyrosine kinase activity of the
receptors is required for activation of Stat1 and Stat3. The EGF
receptor kinase was demonstrated to phosphorylate STATs in vitro
(12, 28, 32). Furthermore, the non-receptor tyrosine kinase,
Src, is involved in the activation of Stat3 by CSF-1 (7).
Compared to cytokine signaling, the mechanisms of Stat3 activation by
growth factors are less defined.
STATs share a highly conserved structure with a number of functional
domains. The three-dimensional structures of the
NH2-terminal domain (N-domain) of Stat4 and the
homodimers of both Stat1 and Stat3
bound to DNA have been
resolved recently (3, 8, 39). The N-domain contains the
NH2-terminal 130 amino acids and is composed of eight
helices assembled into a hook-like structure. This domain is relatively
separated from the other domains in STATs and is not essential for
dimerization or binding to a single-target DNA site, but it mediates
the dimer-dimer interaction and the cooperativity in binding to
multiple DNA sites (38, 42). The crystal structures of Stat1
and Stat3
lacking the N-domain show several conserved domains: an
NH2-terminal coiled-coil domain, a DNA-binding domain, a
linker domain, and an SH2 domain. The phosphotyrosine occurs on residue
705 (3, 8). Forty to fifty amino acids at the carboxyl
termini of STATs that are absent in the crystal structures comprise the
transcriptional activation domain (4) and were recently
reported to be involved in the proteasome-dependent turnover of Stat5
(40). The coiled-coil domain at the amino terminus contains
four antiparallel
-helices and has been inferred to be involved in
protein-protein interaction. For example, residues 150 to 250 of Stat1
(in particular, Lys161, located in helix
1) has been shown to
interact with p48, a protein from an interferon response factor family,
to form interferon (IFN)-stimulated gene factor 3 complex that
regulates IFN-
-responsive genes (19). Recently, a short
region in the first
-helix of the coiled-coil domain and a portion
of the DNA-binding domain of Stat3 have been reported to interact with
another transcription factor, c-Jun, and cooperatively activate
transcription of the IL-6-inducible
2-macroglobulin gene
(45). However, whether this domain plays any role in the
activation and function of STATs is largely unknown.
Here we report that the coiled-coil domain of Stat3 is required for its
tyrosine phosphorylation and phosphotyrosine-dependent activities, including dimerization, nuclear translocation, and DNA
binding stimulated by EGF or IL-6. We further investigated the
mechanism for this regulation and showed that the coiled-coil region is necessary for the recruitment of Stat3 to the cytokine receptor. Furthermore, Asp170, located in the first
-helix, is identified as one of the crucial residues for this regulation. We
propose a novel role for the coiled-coil domain in regulating the
receptor binding and subsequent activation of Stat3.
 |
MATERIALS AND METHODS |
Construction of expression plasmids.
The expression plasmid
of murine Stat3 was obtained from J. E. Darnell, Jr. A series of
NH2-terminal deletion mutants of Stat3 were generated
by PCR using primers containing a BamHI site 5' and
XhoI site 3'. The PCR products were cloned into plasmid
pXJ40-FLAG, a FLAG-tagged expression vector kindly provided
by Z. Zhao (26). Point mutations were prepared by using the
Quikchange site-directed mutagenesis kit (Stratagene) following the
manufacturer's instructions, and mutagenesis was confirmed by standard
dideoxy termination sequencing.
DNA transfection.
COS-1 and HepG2 cells were grown in
Dulbecco's modified Eagle's medium with 10% fetal calf serum
(Gibco-BRL Life Technologies). Transient transfections of the
expression plasmids into COS-1 and HepG2 cells were
performed with Lipofectamine (Gibco-BRL Life Technologies) and
FuGENE 6 transfection reagents (Boehringer Mannheim), respectively,
following the manufacturer's instructions. Half the amount of ST3-
N
was used for transfection because of its extremely high
expression. The cells were lysed and extracted as crude nuclear
extracts for electrophoretic mobility shift assays (EMSA) as
described previously (21).
Antibodies, immunoprecipitation, and immunoblotting.
Antibodies against phospho-Tyr705 and phospho-Ser727 of Stat3 were
purchased from New England Biolabs. Anti-Stat3 (C-20) and anti-FLAG M2
were purchased from Santa Cruz Biotechnology and Sigma, respectively.
Immunoprecipitation and immunoblotting were performed as described
previously (21). In brief, transfected cells were washed
with cold phosphate-buffered saline (PBS) and lysed in
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM
Tris-HCl [pH 7.2], 1% deoxycholic acid, 1% Triton X-100, 0.25 mM
EDTA [pH 8.0] plus 5 µg leupeptin, 5 µg of aprotinin, and 1 µg
of pepstatin A per ml, with 1 mM phenylmethylsulfonyl fluoride, 5 mM NaF, and 100 µM sodium orthovanadate). The cell lysates, containing 1 mg of proteins, were incubated with the appropriate antibody overnight at 4°C, followed by incubation with
protein G PLUS/protein A-agarose (Oncogene Science) for 1 h. The
immunoprecipitates were washed with RIPA buffer and PBS, separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
and transferred to a polyvinylidene difluoride membrane. The membrane
was blocked with PBS containing 0.1% Tween 20 and 1% bovine serum
albumin before it was incubated with the appropriate primary and
secondary antibodies. The bound antibodies were visualized by using BM
Chemiluminescence (Boehringer Mannheim). For a second blotting, the
membrane was incubated in stripping buffer (62.5 mM Tris-HCl [pH
6.8], 2% SDS, 100 mM
-mercaptoethanol) for 30 min at 60°C before reblotting.
Peptide-binding assay.
Transfected cells (107)
were lysed in lysis buffer (1% NP-40, 20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM sodium orthovanadate, 5 µg of aprotinin per ml, and 5 µg of leupeptin per ml). Biotinylated peptides of IL-6 receptor
subunit gp130 (pY2,
SSTVQ-YPO4
-STVVHS;
pY3,
VVHSG-YPO4
-RHQVPS; and
Y3, VVHSGYRHQVPS) were purchased from Sigma-Genosys. The
peptides (5 µg) were incubated with 40 µl of streptavidin-Sepharose (Pierce) at 4°C for 2 h. The beads were washed three times with 20 mM Tris-HCl (pH 7.4) and then incubated with aliquots of lysates (corresponding to ~3 × 106 cells) or 0.5 µg of
the baculovirus-produced Stat3 proteins for 1 h. The complexes
were washed, boiled, fractionated on SDS-PAGE, and blotted with
anti-Stat3 antibody (13, 15).
Expression, purification, and in vitro phosphorylation of
baculovirus-produced Stat3.
BamHI-XhoI cDNA
fragments containing full-length Stat3 and the deletion mutants that
lack the N-domain and
-helices 1 to 4 were cloned into the
baculovirus expression vector pFastBacHT (Gibco-BRL) so that the
recombinant clones were incorporated with a six-histidine residue tag
at the NH2 termini. Sf9 insect cells were transfected with
recombinant bacmid DNAs for the generation of recombinant
baculoviruses. The recombinant baculoviruses were then used for
subsequent infection of the insect cells. For protein expression, Sf9
cells (containing 2 × 106 cells per ml) were infected
with recombinant virus at a multiplicity of infection of 10. Infected
cells were harvested 48 to 72 h later. They were lysed in 10 ml of
lysis buffer (20 mM HEPES [pH 7.9], 100 mM NaCl, 0.5% Nonidet P-40,
15% glycerol, 2 mM 2-mercaptoethanol, 1 mM phenylmethylsulfonyl
fluoride, 10 µg of leupeptin per ml, 1 mM
Na3VO4, 1 mM Na2MoO4,
and 15 mM imidazole) for 1 h. Lysates were then centrifuged for 10 min at 20,000 × g to remove the insoluble components,
and the cleared supernatant was allowed to incubate with
Ni2+ ProBond resin (Invitrogen) for 1 h. The mixture
was packed in a column and extensively washed with lysis buffer
containing 30 mM imidazole. Ni2+-bound proteins were
serially eluted with imidazole at concentrations of 50, 200, 350, and
500 mM. Stat3 proteins were eluted at 200 mM imidazole. The purified
protein was dialyzed against a buffer containing 10 mM HEPES (pH 7.4),
20 mM EDTA, 100 mM NaCl, and 0.5 mM dithiothreitol and stored at
70°C. Purified recombinant Stat3 proteins (2 µg) were
phosphorylated by Src (Upstate Biotechnology) in a buffer containing 10 mM PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid), pH 7.0], 5 mM MnCl2, 1 mM NaCl, 0.1 mM
dithiothreitol, and 20 µM ATP in a volume of 40 µl at 30°C for 20 min. One quarter of the reaction mixture containing 0.5 µg of Stat3
proteins was used for the Western blot analysis or EMSA using
[32P]hSIE, the high-affinity binding site of Stat3, as a probe.
 |
RESULTS |
Coiled-coil domain of Stat3 is required for its tyrosine
phosphorylation and subsequent activation stimulated by EGF or
IL-6.
The coiled-coil domain adjacent to the N-domain of the STAT
proteins consists of four antiparallel helices. To study the structure and function relationship of this domain, we generated a series of
Stat3 mutants that sequentially deleted the N-domain and each of the
four
helices. These constructs were tagged with the FLAG epitope at their amino termini, and the resultant mutants were named
ST3-
N, ST3-
N1H, ST3-
N2H, ST3-
N3H, and ST3-
N4H
(Fig. 1). In our initial analysis, we
examined the tyrosine phosphorylation of the Stat3 mutants in response
to growth factors and cytokines. COS-1 cells, which express a low level
of endogenous Stat3 and respond to EGF strongly, were transfected with
the expression plasmids (41). The cells were either left
untreated or treated with EGF, and tyrosine phosphorylation was
examined by Western blot analysis using an antibody that specifically
recognizes Stat3 proteins phosphorylated on Tyr705. No tyrosine
phosphorylation was detected in the untreated cells, but strong
tyrosine phosphorylation was observed in cells transfected with the
full-length Stat3 (ST3-FL) and the N-domain deletion mutant (ST3-
N)
upon EGF stimulation. On the other hand, tyrosine phosphorylation was
impaired in ST3-
N1H, in which helix
1 was deleted, and was
totally abolished in mutants ST3-
N2H, ST3-
N3H, and ST3-
N4H, in
which two, three, and four
-helices were deleted, respectively (Fig.
2A, upper panel). The expression of the
mutants was comparable (lower panel).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic diagrams of the structural domains and
deletion mutants of Stat3. 1, 2, 3, and 4 represent the
-helices in the coiled-coil region.
|
|

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Tyr phosphorylation of Stat3 deletion mutants stimulated
with EGF or IL-6. (A) COS-1 cells were transfected with control (C) or
Stat3 expression plasmids as labeled and either left untreated or
treated with EGF for 15 min. The cell lysates were prepared and
subjected to Western blot analysis using antibody against an
anti-phospho-Tyr-705-Stat3 (pY705ST3), as indicated in the
upper panel. The membrane was stripped and reprobed with an anti-Stat3
antibody (lower panel). (B) Transfected HepG2 cells were either left
untreated ( ) or treated with IL-6 (+) for 15 min. Cell lysates were
immunoprecipitated (IP) with FLAG antibody, and the immunoprecipitates
were subjected to Western blot analysis using the
anti-pY705ST3 antibody (upper panel). The blots were
stripped and reprobed with Stat3 antibody (lower panel).
|
|
We also examined the tyrosine phosphorylation of the Stat3 mutants in
the human liver hepatoma cell line HepG2, in which the
endogenous Stat3
is strongly tyrosine phosphorylated upon stimulation
with IL-6
(
2). The full-length Stat3 and the deletion mutants
were
transfected into HepG2 cells, and their Tyr705 phosphorylation
was
analyzed by immunoprecipitation and Western blotting. The
results
obtained were very similar to those observed in the EGF-stimulated
COS-1 cells except for ST3-

N, which exhibited a high level of
tyrosine phosphorylation in uninduced cells that was further enhanced
in IL-6-treated cells (Fig.
2B, upper panel). The tyrosine
phosphorylation
of the deletion mutants of the coiled-coil domain was
either inhibited
(ST3-

N1H) or destroyed (ST3-

N2H, ST3-

N3H, and
ST3-

N4H) in
HepG2 cells stimulated by IL-6 (Fig.
2B and data not
shown). These
results indicate that the N-domain is not required for
the tyrosine
phosphorylation of Stat3. In contrast, the helix

1
region is
essential for Stat3 tyrosine phosphorylation stimulated by
EGF
or IL-6.
Phosphorylation on Tyr705 is a prerequisite for STAT activities, such
as dimer formation, nuclear translocation, DNA binding,
and
transactivation. To confirm the above results, we tested the
nuclear
translocation and the DNA-binding activity of these deletion
mutants.
In agreement with the impaired tyrosine phosphorylation,
the

-helix
deletion mutants ST3-

N1H, ST3-

N2H, ST3-

N3H, and
ST3-

N4H
failed to enter the nucleus in either EGF-treated COS-1
or IL-6-treated
rat pheochromocytoma PC12 cells. These mutants
were also unable to bind
hSIE, the high-affinity binding site
of Stat3, as examined by EMSA
(data not shown). Together, these
results demonstrate that the
coiled-coil domain of Stat3 is required
for its tyrosine
phosphorylation and tyrosine phosphorylation-dependent
activities,
including nuclear translocation and DNA
binding.
Both helices
1 and
2 are necessary for the tyrosine
phosphorylation of Stat3.
The above results showed that deletion
of helix
1 abolished the tyrosine phosphorylation of Stat3. However,
involvement of the other helices besides
1 in the regulation of
Stat3 Tyr phosphorylation cannot be excluded. Helices
1 and
2,
spanning 44 and 54 amino acid (aa) residues, respectively, are much
longer than
3 (32 aa) and
4 (25 aa) and represent the major
components of the coiled-coil domain (3). In order to
examine the role of the other helices and to minimize possible
structural disruption due to deletion of the N-domain, we produced two
mutants with a deletion of either helix
1 (ST3-
H1) or
2
(ST3-
H2), with an intact N-domain (see Fig. 1), and their tyrosine
phosphorylation was analyzed. Both deletions totally abrogated their
tyrosine phosphorylation in EGF-induced COS-1 cells (Fig.
3A, upper panel) or in
IL-6-induced HepG2 cells (Fig. 3B, upper panel). The
expressions of these mutants are shown in the lower panels. These data
suggest that both
1 and
2 are necessary for Stat3 tyrosine
phosphorylation.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 3.
Deletion of helix 1 or 2 abolishes tyrosine
phosphorylation of Stat3 in response to EGF or IL-6. COS-1 (A) or HepG2
(B) cells were transfected with the control plasmid (C), full-length
Stat3 (FL), or the mutants in which either helix 1 ( H1) or 2
( H2) was deleted and either left untreated ( ) or treated with EGF
or IL-6 (+). The tyrosine phosphorylation and expression of Stat3 were
monitored by Western blot analysis (A) and immunoprecipitation/blotting
analysis (B,) as described in the legend to Fig. 1.
|
|
Coiled-coil domain of Stat3 is required for its recruitment to the
IL-6 receptor.
In the primary event of STAT activation, STAT
proteins must be recruited to the cytokine receptors via interaction of
their SH2 domains with the specific phosphorylated tyrosine residues on
the cytokine receptors. The cytoplasmic domain of the IL-6 receptor
subunit, gp130, contains six tyrosine residues that are phosphorylated
upon stimulation by IL-6 (Fig. 4A). The
second membrane-proximal tyrosine residue (Y2) is required
for recruitment of the SH2-containing phosphatase-2 (SHP-2), whereas
any one of the four tyrosine residues (Y3 to
Y6) containing the consensus YXXQ motif in the carboxyl
terminus of gp130 can mediate the tyrosine phosphorylation of Stat3
stimulated by IL-6 (1, 34, 43). The 133 amino acids,
including three tyrosine residues (Y1 to Y3),
from the membrane-proximal region of gp130 (shown in Fig. 4A) were
reported to be sufficient to induce cell proliferation (13).
One possible mechanism for the involvement of the coiled-coil domain in
Stat3 phosphorylation is by affecting the protein-protein interaction
between Stat3 and the receptor during the recruitment of Stat3 to the
activated receptor following ligand binding. We examined the ability of
the mutant Stat3 proteins to interact with the phosphorylated receptor
gp130 by coprecipitation analysis using biotinylated forms of the
receptor-derived peptides. The phosphorylated peptide-containing
sequences surrounding the third tyrosine (pY3),
coprecipitated with full-length Stat3 as well as the N-domain mutant
ST3-
N. Surprisingly, binding was diminished in ST3-
N1H and was
totally abolished in ST3-
N2H, ST3-
N3H, and ST3-
N4H. On the
other hand, binding of the wild-type and mutant Stat3 proteins to the
nonphosphorylated peptide Y3 and the phosphopeptide pY2 of the SHP-2 binding site was not observed (Fig. 4B,
upper panel). In addition, the
1 (ST3-
H1) and
2 (ST3-
H2)
deletion mutants also failed to bind the receptor peptide
pY3 (data not shown). These results suggest an involvement
of the coiled-coil domain in receptor binding.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of the coiled-coil domain of Stat3 on its binding
to the phosphorylated peptide derived from IL-6 receptor subunit gp130.
(A) Diagram of the structure and Tyr phosphorylation sites of human
gp130. Y1 to Y6 represent tyrosine residues
683, 759, 767, 814, 905, and 915 on the gp130 cytoplasmic tail,
respectively. TM, transmembrane domain. a.a., amino acids. (B) COS-1
cells were transfected with the Stat3 plasmids as labeled on top of the
upper panel and lysed after 48 h. The biotinylated peptides
(pY2,
SSTVQ-YPO4 -STVVHS;
pY3,
VVHSG-YPO4 -RHQVPS; and
Y3, VVHSGYRHQVPS) derived from gp130 were incubated with
streptavidin-Sepharose. The beads were washed and then incubated with
aliquots of lysates. The complexes were washed, fractionated on
SDS-PAGE, and immunoblotted with anti-Stat3 antibody (upper panel). The
cell lysates were subjected to Western blot analysis with anti-Stat3
antibody to monitor the expression of the various Stat3 proteins in
transfected cells (lower panel). (C) The blot used in panel B was
stripped and reprobed with anti-SHP-2 antibody. Binding of the
endogenous SHP-2 from cells transfected with full-length Stat3 to its
docking site pY2 is shown.
|
|
It is well known that the SH2 domain is required for STAT protein
binding to cytokine receptors. An arginine residue conserved
in
all known SH2 domains recognizes the phosphate group of the
phosphotyrosine (
23,
27). Arg602 in Stat1 and Arg609
in Stat3
are such key residues (
3,
8). To confirm the
essential role
of the SH2 domain in receptor binding in our
system, a point mutation
on the SH2 domain of Stat3, ST3R609L,
was produced by replacing
Arg609 with Leu. This mutation totally
abolished its peptide-binding
ability (Fig.
4B, upper panel). The
expression level of the various
Stat3 proteins in the transfected COS-1
cells was comparable (lower
panel of Fig.
4B). A strong binding of
endogenous SHP-2 to pY
2,
but not to Y
3 and
pY
3, was detected in COS-1 cells, indicating
the
specificity of the peptide-binding experiment (Fig.
4C). Similar
binding patterns for the full-length, deletion, and SH2 mutants
were
also observed in transfected HepG2 cells (data not shown).
These
results indicate that both the SH2 domain and the coiled-coil
domain
are necessary for the interaction between Stat3 and the
IL-6 receptor,
and loss of tyrosine phosphorylation in the coiled-coil
deletion
mutants is due to a deficiency in receptor
binding.
Single point mutation Asp170 in helix
1 of the coiled-coil
region of Stat3 diminishes its interaction with gp130 and tyrosine
phosphorylation.
How does the coiled-coil domain affect receptor
binding? It is possible that the deletion mutations of the coiled-coil
region used in this study may result in a change in protein
conformation that alters the structure of the SH2 domain. To address
this issue, four highly conserved hydrophilic amino acid residues which
are distributed along the helix
1 region were chosen for
site-directed mutagenesis (Fig. 5A). Each
of these residues was replaced with alanine, and the receptor binding
activity of the mutants was examined. Two mutants, R152A (Arg152
Ala)
and K163A (Lys163
Ala), showed similar binding affinity to
pY3 in comparison with wild-type Stat3. In contrast,
binding of mutants D170A (Asp170
Ala) and K177A (Lys177
Ala),
albeit less dramatic, was diminished. The expression levels of these
mutants and the wild-type Stat3 were equivalent (Fig. 5B). In agreement
with this, the tyrosine phosphorylation of D170A and K177A but not
R152A and K163A was significantly reduced in response to EGF (Fig. 5C,
upper panel).

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 5.
Point mutant Asp170 of Stat3 diminishes its
peptide-binding activity and the tyrosine phosphorylation stimulated by
EGF. (A) Sequence alignment of helix 1 in the coiled-coil domain of
STATs. The highly conserved hydrophilic residues are boxed and
indicated at the bottom. (B) COS-1 cells were transfected with point
mutants of Stat3 as labeled on top of the upper panel. The
peptide-binding experiments were performed as described in the legend
to Fig. 4. The expression of the mutant Stat3 proteins is examined in
Western blot analysis in the lower panel. (C) COS-1 cells were
transfected with control vector or Stat3 plasmids as labeled on top of
the upper panel and induced by EGF for 15 min. The cell lysates were
subjected to Western blot analysis with antibodies against
phospho-Tyr-705-Stat3 (upper panel) or Stat3 (lower panel).
|
|
Analysis of the crystal structure of Stat3

together with molecular
modeling revealed that Arg152 has a side chain pointing
towards the
interface between helix

1 and helix

3, whereas the
other three
residues have side chains pointing away from the interface
and are
unlikely to interact with helix

3 (not shown). The results
showed
that the R152A mutation has no effect on receptor binding,
suggesting
that its SH2 domain is intact. Therefore, the decreased
receptor
binding caused by mutations on surface residues Asp170
and Lys177 is
unlikely due to a major conformational change of
the coiled-coil domain
or the SH2 domain. These data also suggest
that Asp170 and, to a lesser
extent, Lys177 may function as critical
residues in the regulation of
receptor
binding.
Stat3 protein lacking helix
1 of the coiled-coil domain retains
a functional SH2 domain.
The SH2 domains of STAT proteins possess
a unique dual role in their activation. They are required for
recruitment to the receptors and participate in dimer formation by
reciprocal interaction with the specific phosphotyrosine residue at the
carboxyl termini of the STAT proteins. To further determine whether the
SH2 domain is functional in the deletion mutant, mutant Stat3 which
lacks the N-domain and helix
1 (b-ST3-
N1H) and full-length Stat3
(b-ST3-FL) were expressed and purified in the baculovirus expression
system. The recombinant proteins were phosphorylated with Src kinase in vitro, and tyrosine phosphorylation and DNA-binding activity were examined. As shown in Fig. 6, strong Tyr
phosphorylation by Src was detected in both the wild type and the
deletion mutant. Correspondingly, upon phosphorylation, both
proteins bound DNA with similar affinities, as determined by EMSA. The
amounts of two proteins used in the above assays are shown in the lower
panel of Fig. 6A. These results demonstrate that b-ST3-
N1H serves as
a proper substrate for Src kinase and is able to bind DNA after
phosphorylation, suggesting that its SH2 domain is functionally intact.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 6.
Phosphorylation and DNA binding of the helix 1
deletion mutant in vitro. Baculovirus-expressed full-length Stat3
(b-ST3-FL) and Stat3 with deletions of the N-domain and helix 1
(b-ST3- N1H) were purified from Sf9 cells and incubated with Src
kinase. The reaction mixture was divided so that each part contained
0.5 µg of Stat3 proteins and subjected to either Western blot
analysis with the antibodies indicated (A) or EMSA using
[32P]hSIE as a probe (B). FP, free probe.
|
|
Direct interaction of Stat3 with the gp130-derived
phosphopeptide.
To further determine whether Stat3 interacts
directly with the gp130 receptor, baculovirus-produced b-ST3-FL,
b-ST3-
N1H, and b-ST3-
N4H (deleting four
-helices) were
purified, and their receptor-binding abilities were analyzed by the
peptide-binding assay. Similar to the results obtained in vivo (Fig.
4), we observed a strong interaction between wild-type Stat3 and the
gp130-derived phosphopeptide pY3, but not Y3 (Fig.
7, lanes 1 and 2). The binding was
significantly diminished for b-ST3-
N1H (lane 3) and totally abrogated for b-ST3-
N4H (lane 5). These data demonstrate that Stat3
is able to interact directly with its phosphorylated docking site on
the gp130 receptor without the participation of an adaptor protein.
These results also indicate that the deficiency of b-ST3-
N1H in
receptor binding is unlikely to be due to a lack of interaction with
other proteins.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 7.
Direct interaction of Stat3 and the gp130-derived
phosphopeptide. Baculovirus-expressed full-length Stat3 (b-ST3-FL) and
the deletion mutants (b-ST3- N1H and b-ST3- N4H) were purified from
Sf9 cells, and 0.5 µg of each protein was subjected to peptide
binding with either pY3 or Y3 as described in the legend to Fig. 4
(upper panel) or Western blot analysis (lower panel).
|
|
 |
DISCUSSION |
The crystal structures of Stat1 and Stat3
exhibit highly
conserved structural features, including newly defined domains such as
the linker domain and the coiled-coil domain (3, 8). These
data provide insight into the function of each domain. The coiled-coil
domain is commonly related to the protein-protein interaction
(22). Although this domain of Stat3 consists of 182 amino
acids that occupy approximately one fourth of the whole molecule, its
function is largely unknown. Our systematic studies on this region for
the first time reveal its pivotal role in the regulation of Stat3
tyrosine phosphorylation stimulated by EGF or IL-6. It is well
established that tyrosine phosphorylation is a prerequisite for
STAT activation. In our experiments, tyrosine phosphorylation-dependent
activities, such as dimerization, nuclear translocation, and the
DNA binding of Stat3, were all abrogated by deletion of one to
four
helices (data not shown). Although such inhibitory effects
could be due simply to a deficiency of tyrosine phosphorylation but not
to the effect on the activities per se, the possibility that the
coiled-coil region has other functions cannot be excluded and requires
further investigation.
The first step for STATs becoming tyrosine phosphorylated is their
recruitment to the receptors of the polypeptide ligands. The SH2
domains of the STAT proteins interact with specific tyrosine residues
on the cytokine receptors, which facilitate their subsequent tyrosine
phosphorylation by the receptor-associated JAKs (16, 17,
34). To understand the mechanisms of the coiled-coil region regulating the tyrosine phosphorylation of Stat3, we examined the
ability of the wild-type and the mutant Stat3 proteins binding to the
IL-6 receptor subunit, gp130. Our results demonstrate that deletion of
helix
1 and/or
2 abolishes the binding of Stat3 to the receptor.
Although the binding experiments were performed with peptides derived
from gp130, activation of Stat3 by EGF could be mediated in a similar
way. Two autophosphorylated tyrosine residues containing the consensus
YXXQ binding site of Stat3 on the EGF receptor have been identified as
critical for Stat3 activation (9). Correspondingly, we have
observed that the SH2 domain is also required for Stat3 induction by
EGF (data not shown), suggesting that the binding of Stat3 to the EGF
receptor by its SH2 domain is necessary for its subsequent tyrosine
phosphorylation. Moreover, the tyrosine phosphorylation profiles of the
deletion and point mutants of Stat3 induced by EGF and IL-6 were
similar. These data suggest that in addition to the SH2 domain, the
coiled-coil domain is also required for the recruitment of Stat3 to
both the cytokine and growth factor receptors.
We further addressed the mechanisms of how the coiled-coil domain is
involved in the binding of Stat3 to the receptor. One possibility is
that the binding is independently mediated either by the coiled-coil
domain or by the SH2 domain. However, this is unlikely because our
results indicate that either the coiled-coil mutations or the SH2
mutation eliminates binding. Another possibility is that both are
required for efficient receptor binding. The coiled-coil domain may
modulate SH2 domain binding activity or vice versa. Given the
considerable evidence on critical interaction between the SH2 domain
and phosphotyrosine residue on the receptor and the binding specificity
of the Stat3 SH2 domain to the phosphopeptide pY3 shown in
our experiments (Fig. 4 and 5), it is more likely that the coiled-coil
domain affects the SH2 domain binding to the receptor, but not the reverse.
One possible mechanism by which the coiled-coil domain regulates the
SH2 domain binding to receptor is that the coiled-coil domain may
affect the structure of the SH2 domain so that in its absence the
conformation of the SH2 domain is altered. The data we have presented
so far argue against this. Based on the structure of Stat3 dimer bound
to DNA, the coiled-coil domain is physically separated from the SH2
domain by two other structural domains, the DNA-binding domain and the
linker domain. It is unlikely that any local structural perturbation
that happens in the coiled-coil region at the amino terminus directly
affects the SH2 domain at the carboxyl terminus. Furthermore, to
minimize possible structural disruption, we mutated four highly
conserved, hydrophilic amino acid residues in the helix
1 region and
analyzed the side chain interactions involving these residues. We
believe that if there is any effect of these mutations on the structure
of Stat3, it is likely to be restricted to the coiled-coil region and
unlikely to cause a global conformational change that leads to
distortion of the SH2 domain. First, these four amino acids are exposed
residues and do not form part of the buried residues contributing to
the interaction essential for structural integrity of the four-helix bundles of the coiled-coil domain (24). Second, three of the four residues have side chains which do not point towards the interface
between either helices 1 and 3 or helices 1 and 2. Mutations in any of
these residues are therefore unlikely to disrupt the interactions
between helices. Arg152, the only residue among the four with a side
chain that forms hydrogen bonds with Ser269 and Glu272 of helix 3 (data not shown), has no detectable effect on the SH2 function when it
is mutated. In addition, we demonstrate that a baculovirus-expressed
Stat3 mutant, b-ST3-
N1H, carrying the helix
1 deletion, is
capable of binding DNA after Tyr705 phosphorylation by Src kinase in
vitro (Fig. 6B). These results confirm that the deletion mutant of the
1 helix retains its capacity to form dimer, which indirectly
suggests that its SH2 domain remains functional.
The latter result, on the other hand, also raises the question of why
ST3-
N1H fails to bind to the receptor and yet can form dimers. We
compared the binding affinities of the wild-type and mutant Stat3 to
the gp130-derived phosphopeptide (pY3) and to the Stat3
Tyr705-derived phosphopeptide. The results showed that both transfected
and baculovirus-expressed Stat3 binds to its own peptide with
affinities that are 25- and 50-fold lower than those of gp130 peptide,
respectively. In the case of the mutant ST3-
N1H, binding to the
gp130 peptide was diminished and to the Stat3 Y705 peptide was almost
undetectable (data not shown). These results are consistent with those
of similar experiments performed in Stat1 (15). The affinity
of Stat1 binding to the IFN-
receptor phosphopeptide is 110 times
higher than binding to the Stat1 phosphopeptide, indicating that the
latent form of Stat1 interacts preferentially with its docking
site on the receptor. However, the phosphorylated Stat1 subsequently
forms a high-avidity complex through reciprocal interactions between
the SH2 domains and the phosphotyrosines of two monomers, and the
dimerized Stat1 is unlikely to rebind to the receptor. It has been
suggested that Stat1 recruitment to the receptor, dissociation from the
receptor after phosphorylation, and subsequent dimerization are an
ordered process driven by affinity. The unidirectional release of
activated Stat1 from the IFN-
receptor indicates the preference of
free tyrosine-phosphorylated Stat1 monomers to form high-avidity
reciprocal homodimers rather than reassociating with the receptor
binding site. Our experiments suggest that Stat3 activation may follow
a similar process. The activation process involves two phases, before
and after phosphorylation. Prior to phosphorylation, Stat3 is recruited
to the receptor with high affinity. Once Tyr705 is phosphorylated,
disassociation from the receptor is driven perhaps by the formation of
an energetically more favorable dimer. In our experiment, after Stat3
and mutant ST3-
N1H are phosphorylated by Src in vitro, dimerization
and subsequent DNA binding occur. This could partially explain why ST3-
N1H can form a dimer although it fails to bind to the receptor.
The second mechanism could be that the deletion and point mutations in
the coiled-coil domain cause the protein to fold in such a manner that
the binding of the SH2 domain pocket by the peptide is precluded or
masked. Based on the structural studies, the coiled-coil domain of
Stat1 and Stat3
presents a predominantly hydrophilic surface area
for interaction with other proteins (3, 8). Although it is
unlikely that the coiled-coil domain interacts directly with the
receptor peptide, it is possible that this domain regulates the
accessibility of the SH2 domain for peptide binding via interactions
with either another protein(s) or another domain(s) within the Stat3
protein. Since we have shown that the receptor binding of Stat3 does
not require other proteins in vitro and the unlikely destruction of the
SH2 domain in the point mutants, our hypothesis is that regulation of
SH2 domain binding to the receptor may be mediated by an
intramolecular interaction that involves the coiled-coil domain.
Removal of the first
-helix, or more specifically mutation of the
two surface residues Asp170 and Lys177, may result in loss of the
intramolecular interaction which is essential to maintain SH2 domain
accessibility to receptor binding but not for dimer formation. The
proposed hypothesis is currently under investigation.
Stat3 plays an essential role in embryonic development, as well as in
growth and differentiation of hematopoietic cells (18, 30,
35). Increasing evidence also shows an important role for Stat3
in oncogenesis. For example, Stat3 is constitutively activated in
v-Src-transformed cells (7, 44) and plays a crucial role in
the transformation of cells by v-Src (5, 36). Furthermore,
constitutively activated Stat3 has been found in many tumor cell lines
and primary tumors (14). More strikingly, Stat3 itself has
been identified as an oncogene when it is spontaneously dimerized
(6). Therefore, understanding the mechanisms that control
Stat3 activation may provide useful information for cancer therapies,
and the coiled-coil region of Stat3 may be a useful target for drug
design and screening of small molecules that inhibit Stat3 activity by
disruption of this domain.
 |
ACKNOWLEDGMENTS |
We thank J. E. Darnell, Jr., for plasmid pRC/CMV-Stat3 and
E. Manser and L. Lim for the pXJ40-FLAG vector, Cheh Peng Lim for reading the manuscript, Robert Qi for helpful suggestions for the
peptide-binding experiments, and R. Tham for photography.
K. T. Seow is a Structural Bioinformatics Scientist. This work was
supported by the National Science and Technology Board of Singapore.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Molecular and Cell Biology, 30 Medical Drive, Singapore 117609, Singapore. Phone: (65) 874-3795. Fax: (65) 779-1117. E-mail:
mcbcaoxm{at}imcb.nus.edu.sg.
Present address: Marine Biotechnology Laboratory, Department of
Biological Sciences, National University of Singapore, Singapore 117543, Singapore.
 |
REFERENCES |
| 1.
|
Adachi, M.,
E. H. Fischer,
J. Ihle,
K. Imai,
F. Jirik,
B. Neel,
T. Pawson,
S. Shen,
M. Thomas,
A. Ullrich, and Z. Zhao.
1996.
Mammalian SH2-containing protein tyrosine phosphatases.
Cell
85:15[CrossRef][Medline].
|
| 2.
|
Akira, S.,
Y. Nishio,
M. Inoue,
X. J. Wang,
S. Wei,
T. Matsusaka,
K. Yoshida,
T. Sudo,
M. Naruto, and T. Kishimoto.
1994.
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway.
Cell
77:63-71[CrossRef][Medline].
|
| 3.
|
Becker, S.,
B. Groner, and C. M. Müller.
1998.
Three-dimensional structure of the Stat3 homodimer bound to DNA.
Nature
394:145-151[CrossRef][Medline].
|
| 4.
|
Bhattacharya, S.,
R. Eckner,
S. Grossman,
E. Oldread,
Z. Arany,
A. D'Andrea, and D. M. Livingston.
1996.
Cooperation of Stat2 and p300/CBP in signalling induced by interferon- .
Nature
383:344-347[CrossRef][Medline].
|
| 5.
|
Bromberg, J. F.,
C. M. Horvath,
D. Besser,
W. W. Lathem, and J. E. Darnell, Jr.
1998.
Stat3 activation is required for cellular transformation by v-src.
Mol. Cell. Biol.
18:2553-2558[Abstract/Free Full Text].
|
| 6.
|
Bromberg, J. F.,
M. H. Wrzeszczynska,
G. Devgan,
Y. Zhao,
R. G. Pestell,
C. Albanese, and J. E. Darnell, Jr.
1999.
Stat3 as an oncogene.
Cell
98:295-303[CrossRef][Medline].
|
| 7.
|
Cao, X.,
A. Tay,
G. R. Guy, and Y. H. Tan.
1996.
Activation and association of Stat3 with Src in v-Src-transformed cell lines.
Mol. Cell. Biol.
16:1595-1603[Abstract].
|
| 8.
|
Chen, X.,
U. Vinkemeier,
Y. Zhao,
D. Jeruzalmi,
J. E. Darnell, Jr., and J. Kuriyan.
1998.
Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA.
Cell
93:827-839[CrossRef][Medline].
|
| 9.
|
Coffer, P. J., and W. Kruijer.
1995.
EGF receptor deletions define a region specifically mediating STAT transcription factor activation.
Biochem. Biophys. Res. Commun.
210:74-81[CrossRef][Medline].
|
| 10.
|
Darnell, J. E., Jr.
1997.
STATs and gene regulation.
Science
277:1630-1635[Abstract/Free Full Text].
|
| 11.
|
Darnell, J. E., Jr.,
I. M. Kerr, and G. R. Stark.
1994.
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
Science
264:1415-1421[Abstract/Free Full Text].
|
| 12.
|
Fu, X.-Y., and J.-J. Zhang.
1993.
Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter.
Cell
74:1135-1145[CrossRef][Medline].
|
| 13.
|
Fukada, T.,
M. Hibi,
Y. Yamanaka,
M. Takahashi-Tezuka,
Y. Fujitani,
T. Yamaguchi,
K. Nakajima, and T. Hirano.
1996.
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis.
Immunity
5:449-460[CrossRef][Medline].
|
| 14.
|
Garcia, R., and R. Jove.
1998.
Activation of STAT transcription factors in oncogenic tyrosine kinase signaling.
J. Biomed. Sci.
5:79-85[Medline].
|
| 15.
|
Greenlund, A. C.,
M. O. Morales,
B. L. Viviano,
H. Yan,
J. Krolewski, and R. D. Schreiber.
1995.
Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process.
Immunity
2:677-687[CrossRef][Medline].
|
| 16.
|
Heim, M. H.,
I. M. Kerr,
G. R. Stark, and J. E. Darnell, Jr.
1995.
Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway.
Science
267:1347-1349[Abstract/Free Full Text].
|
| 17.
|
Hemmann, U.,
C. Gerhartz,
B. Heesel,
J. Sasse,
G. Kurapkat,
J. Grötzinger,
A. Wollmer,
Z. Zhong,
J. E. Darnell, Jr.,
L. Graeve,
P. C. Heinrich, and F. Horn.
1996.
Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of Stat factor activation.
J. Biol. Chem.
271:12999-13007[Abstract/Free Full Text].
|
| 18.
|
Hirano, T.,
K. Nakajima, and M. Hibi.
1997.
Signaling mechanisms through gp130: a model of the cytokine system.
Cytokine Growth Factor Rev.
8:241-252[CrossRef][Medline].
|
| 19.
|
Horvath, C. M.,
G. R. Stark,
I. M. Kerr, and J. E. Darnell, Jr.
1996.
Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex.
Mol. Cell. Biol.
16:6957-6964[Abstract].
|
| 20.
|
Ihle, J. N.
1996.
STATs: signal transducers and activators of transcription.
Cell
84:331-334[CrossRef][Medline].
|
| 21.
|
Jain, N.,
T. Zhang,
W. H. Kee,
W. Li, and X. Cao.
1999.
Protein kinase C associates with and phosphorylates Stat3 in an interleukin-6-dependent manner.
J. Biol. Chem.
274:24392-24400[Abstract/Free Full Text].
|
| 22.
|
Kammerer, R. A.
1997.
Alpha-helical coiled-coil oligomerization domains in extracellular proteins.
Matrix Biol.
15:555-565[CrossRef][Medline].
|
| 23.
|
Kuriyan, J., and D. Cowburn.
1997.
Modular peptide recognition domains in eukaryotic signaling.
Annu. Rev. Biophys. Biomol. Struct.
26:259-288[CrossRef][Medline].
|
| 24.
|
Lumb, K. J., and P. S. Kim.
1995.
A buried polar interaction imparts structural uniqueness in a designed heterodimeric coiled coil.
Biochemistry
34:8642-8648[CrossRef][Medline].
|
| 25.
|
Lütticken, C.,
U. M. Wegenka,
J. Yuan,
J. Buschmann,
C. Schindler,
A. Ziemiecki,
A. G. Harpur,
A. F. Wilks,
K. Yasukawa,
T. Taga,
T. Kishimoto,
G. Barbieri,
S. Pellegrini,
M. Sendtner,
P. C. Heinrich, and F. Horn.
1994.
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.
Science
263:89-92[Abstract/Free Full Text].
|
| 26.
|
Manser, E.,
T. H. Loo,
C. G. Koh,
Z. S. Zhao,
X. Q. Chen,
L. Tan,
I. Tan,
T. Leung, and L. Lim.
1998.
PAK kinases are directly coupled to the PIX family of nucleotide exchange factors.
Mol. Cell
2:183-192[CrossRef][Medline].
|
| 27.
|
Pawson, T.
1995.
Protein modules and signalling networks.
Nature
373:573-580[CrossRef][Medline].
|
| 28.
|
Quelle, F. W.,
W. Thierfelder,
B. A. Witthuhn,
B. Tang,
S. Cohen, and J. N. Ihle.
1995.
Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor.
J. Biol. Chem.
270:20775-20780[Abstract/Free Full Text].
|
| 29.
|
Sadowski, H. B.,
K. Shuai,
J. E. Darnell, Jr., and M. Z. Gilman.
1993.
A common nuclear signal transduction pathway activated by growth factor and cytokine receptors.
Science
261:1739-1744[Abstract/Free Full Text].
|
| 30.
|
Schindler, C., and J. E. Darnell, Jr.
1995.
Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.
Annu. Rev. Biochem.
64:621-651[Medline].
|
| 31.
|
Shuai, K.,
C. M. Horvath,
L. H. Huang,
S. A. Qureshi,
D. Cowburn, and J. E. Darnell, Jr.
1994.
Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions.
Cell
76:821-828[CrossRef][Medline].
|
| 32.
|
Silvennoinen, O.,
C. Schindler,
J. Schlessinger, and D. E. Levy.
1993.
Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation.
Science
261:1736-1739[Abstract/Free Full Text].
|
| 33.
|
Stahl, N.,
T. G. Boulton,
T. Farruggella,
N. Y. Ip,
S. Davis,
B. A. Witthuhn,
F. W. Quelle,
O. Silvennoinen,
G. Barbieri,
S. Pellegrini,
J. N. Ihle, and G. D. Yancopoulos.
1994.
Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.
Science
263:92-95[Abstract/Free Full Text].
|
| 34.
|
Stahl, N.,
T. J. Farruggella,
T. G. Boulton,
Z. Zhong,
J. E. Darnell, Jr., and G. D. Yancopoulos.
1995.
Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors.
Science
267:1349-1353[Abstract/Free Full Text].
|
| 35.
|
Takeda, K.,
K. Noguchi,
W. Shi,
T. Tanaka,
M. Matsumoto,
N. Yoshida,
T. Kishimoto, and S. Akira.
1997.
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.
Proc. Natl. Acad. Sci. USA
94:3801-3804[Abstract/Free Full Text].
|
| 36.
|
Turkson, J.,
T. Bowman,
R. Garcia,
E. Caldenhoven,
R. P. De Groot, and R. Jove.
1998.
Stat3 activation by Src induces specific gene regulation and is required for cell transformation.
Mol. Cell. Biol.
18:2545-2552[Abstract/Free Full Text].
|
| 37.
|
Van Snick, J.
1990.
Interleukin-6: an overview.
Annu. Rev. Immunol.
8:253-278[Medline].
|
| 38.
|
Vinkemeier, U.,
S. L. Cohen,
I. Moarefi,
B. T. Chait,
J. Kuriyan, and J. E. Darnell, Jr.
1996.
DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites.
EMBO J.
15:5616-5626[Medline].
|
| 39.
|
Vinkemeier, U.,
I. Moarefi,
J. E. Darnell, Jr., and J. Kuriyan.
1998.
Structure of the amino-terminal protein interaction domain of STAT-4.
Science
279:1048-1052[Abstract/Free Full Text].
|
| 40.
|
Wang, D. M.,
R. Moriggl,
D. Stravopodis,
N. Carpino,
J.-C. Marine,
S. Teglund,
J. Feng, and J. N. Ihle.
2000.
A small amphipathic -helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5.
EMBO J.
19:392-399[CrossRef][Medline].
|
| 41.
|
Wen, Z.,
Z. Zhong, and J. E. Darnell, Jr.
1995.
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
Cell
82:241-250[CrossRef][Medline].
|
| 42.
|
Xu, X.,
Y. L. Sun, and T. Hoey.
1996.
Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain.
Science
273:794-797[Abstract].
|
| 43.
|
Yamanaka, Y.,
K. Nakajima,
T. Fukada,
M. Hibi, and T. Hirano.
1996.
Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation.
EMBO J.
15:1557-1565[Medline].
|
| 44.
|
Yu, C. L.,
D. J. Meyer,
G. S. Campbell,
A. C. Larner,
C. Carter-Su,
J. Schwartz, and R. Jove.
1995.
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.
Science
269:81-83[Abstract/Free Full Text].
|
| 45.
|
Zhang, X.,
M. H. Wrzeszczynska,
C. M. Horvath, and J. E. Darnell, Jr.
1999.
Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation.
Mol. Cell. Biol.
19:7138-7146[Abstract/Free Full Text].
|
| 46.
|
Zhong, Z.,
Z. Wen, and J. E. Darnell, Jr.
1994.
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.
Science
264:95-98[Abstract/Free Full Text].
|
Molecular and Cellular Biology, October 2000, p. 7132-7139, Vol. 20, No. 19
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sud, N., Kumar, S., Wedgwood, S., Black, S. M.
(2009). Modulation of PKC{delta} signaling alters the shear stress-mediated increases in endothelial nitric oxide synthase transcription: role of STAT3. Am. J. Physiol. Lung Cell. Mol. Physiol.
296: L519-L526
[Abstract]
[Full Text]
-
Yang, G., Lim, C.-Y., Li, C., Xiao, X., Radda, G. K., Li, C., Cao, X., Han, W.
(2009). FoxO1 Inhibits Leptin Regulation of Pro-opiomelanocortin Promoter Activity by Blocking STAT3 Interaction with Specificity Protein 1. J. Biol. Chem.
284: 3719-3727
[Abstract]
[Full Text]
-
Bong, Y.-S., Lee, H.-S., Carim-Todd, L., Mood, K., Nishanian, T. G., Tessarollo, L., Daar, I. O.
(2007). ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3. Proc. Natl. Acad. Sci. USA
104: 17305-17310
[Abstract]
[Full Text]
-
Herrmann, A., Vogt, M., Monnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., Muller-Newen, G.
(2007). Nucleocytoplasmic shuttling of persistently activated STAT3. J. Cell Sci.
120: 3249-3261
[Abstract]
[Full Text]
-
Gartsbein, M., Alt, A., Hashimoto, K., Nakajima, K., Kuroki, T., Tennenbaum, T.
(2006). The role of protein kinase C {delta} activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation. J. Cell Sci.
119: 470-481
[Abstract]
[Full Text]
-
Ng, D. C. H., Lin, B. H., Lim, C. P., Huang, G., Zhang, T., Poli, V., Cao, X.
(2006). Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. JCB
172: 245-257
[Abstract]
[Full Text]
-
Hao, A., Novotny-Diermayr, V., Bian, W., Lin, B., Lim, C. P., Jing, N., Cao, X.
(2005). The LIM/Homeodomain Protein Islet1 Recruits Janus Tyrosine Kinases and Signal Transducer and Activator of Transcription 3 and Stimulates Their Activities. Mol. Biol. Cell
16: 1569-1583
[Abstract]
[Full Text]
-
Schroder, M., Kroeger, K. M., Volk, H.-D., Eidne, K. A., Grutz, G.
(2004). Preassociation of nonactivated STAT3 molecules demonstrated in living cells using bioluminescence resonance energy transfer: a new model of STAT activation?. J. Leukoc. Biol.
75: 792-797
[Abstract]
[Full Text]
-
Yu, Z., Kone, B. C.
(2004). The STAT3 DNA-Binding Domain Mediates Interaction with NF-{kappa}B p65 and Inducible Nitric Oxide Synthase Transrepression in Mesangial Cells. J. Am. Soc. Nephrol.
15: 585-591
[Abstract]
[Full Text]
-
Chang, H.-C., Zhang, S., Oldham, I., Naeger, L., Hoey, T., Kaplan, M. H.
(2003). STAT4 Requires the N-terminal Domain for Efficient Phosphorylation. J. Biol. Chem.
278: 32471-32477
[Abstract]
[Full Text]
-
Ma, J., Zhang, T., Novotny-Diermayr, V., Tan, A. L. C., Cao, X.
(2003). A Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation. J. Biol. Chem.
278: 29252-29260
[Abstract]
[Full Text]
-
Novotny-Diermayr, V., Zhang, T., Gu, L., Cao, X.
(2002). Protein Kinase C delta Associates with the Interleukin-6 Receptor Subunit Glycoprotein (gp) 130 via Stat3 and Enhances Stat3-gp130 Interaction. J. Biol. Chem.
277: 49134-49142
[Abstract]
[Full Text]
-
Zhang, T., Seow, K. T., Ong, C. T., Cao, X.
(2002). Interdomain Interaction of Stat3 Regulates Its Src Homology 2 Domain-mediated Receptor Binding Activity. J. Biol. Chem.
277: 17556-17563
[Abstract]
[Full Text]
-
Maurer, A. B., Wichmann, C., Gross, A., Kunkel, H., Heinzel, T., Ruthardt, M., Groner, B., Grez, M.
(2002). The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood
99: 2647-2652
[Abstract]
[Full Text]
-
Zhang, Y., Liu, G., Dong, Z.
(2001). MSK1 and JNKs Mediate Phosphorylation of STAT3 in UVA-irradiated Mouse Epidermal JB6 Cells. J. Biol. Chem.
276: 42534-42542
[Abstract]
[Full Text]